ABSTRACT
The mTOR kinase regulates a variety of critical cellular processes and has become a target for the treatment of various cancers. Using a combination of property-based drug design and Free-Wilson analysis, we further optimized a series of selective mTOR inhibitors based on the (S)-6a-methyl-6a,7,9,10-tetrahydro[1,4]oxazino[3,4-h]pteridin-6(5H)-one scaffold. Our efforts resulted in 14c, which showed similar in vivo efficacy compared to previous lead 1 at 1/15 the dose, a result of its improved drug-like properties.
ABSTRACT
Target-engagement pharmacodynamic (PD) biomarkers are valuable tools in the prioritization of drug candidates, especially for novel, first-in-class mechanisms whose robustness to alter disease outcome is unknown. Methionine aminopeptidase 2 (MetAP2) is a cytosolic metalloenzyme that cleaves the N-terminal methionine from nascent proteins. Inhibition of MetAP2 leads to weight loss in obese rodents, dogs and humans. However, there is a need to develop efficacious compounds that specifically inhibit MetAP2 with an improved safety profile. The objective of this study was to identify a PD biomarker for selecting potent, efficacious compounds and for predicting clinical efficacy that would result from inhibition of MetAP2. Here we report the use of NMet14-3-3γ for this purpose. Treatment of primary human cells with MetAP2 inhibitors resulted in an approx. 10-fold increase in NMet14-3-3γ levels. Furthermore, treatment of diet-induced obese mice with these compounds reduced body weight (approx. 20%) and increased NMet14-3-3γ (approx. 15-fold) in adipose tissues. The effects on target engagement and body weight increased over time and were dependent on dose and administration frequency of compound. The relationship between compound concentration in plasma, NMet14-3-3γ in tissue, and reduction of body weight in obese mice was used to generate a pharmacokinetic-pharmacodynamic-efficacy model for predicting efficacy of MetAP2 inhibitors in mice. We also developed a model for predicting weight loss in humans using a target engagement PD assay that measures inhibitor-bound MetAP2 in blood. In summary, MetAP2 target engagement biomarkers can be used to select efficacious compounds and predict weight loss in humans. SIGNIFICANCE STATEMENT: The application of target engagement pharmacodynamic biomarkers during drug development provides a means to determine the dose required to fully engage the intended target and an approach to connect the drug target to physiological effects. This work exemplifies the process of using target engagement biomarkers during preclinical research to select new drug candidates and predict clinical efficacy. We determine concentration of MetAP2 antiobesity compounds needed to produce pharmacological activity in primary human cells and in target tissues from an appropriate animal model and establish key relationships between pharmacokinetics, pharmacodynamics, and efficacy, including the duration of effects after drug administration. The biomarkers described here can aid decision-making in early clinical trials of MetAP2 inhibitors for the treatment of obesity.
Subject(s)
Chlorobenzenes/pharmacology , Cinnamates/pharmacology , Cyclohexanes/pharmacology , Epoxy Compounds/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Methionyl Aminopeptidases/antagonists & inhibitors , Methionyl Aminopeptidases/metabolism , Sesquiterpenes/pharmacology , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/pharmacology , Animals , Biomarkers/metabolism , Chlorobenzenes/chemistry , Cinnamates/chemistry , Cyclohexanes/chemistry , Dose-Response Relationship, Drug , Epoxy Compounds/chemistry , HeLa Cells , Humans , Male , Mice , Mice, Inbred C57BL , Predictive Value of Tests , Sesquiterpenes/chemistry , Treatment OutcomeABSTRACT
[This corrects the article DOI: 10.1021/acsmedchemlett.6b00481.].
ABSTRACT
Guided by co-crystal structural information obtained from a different series we were exploring, a scaffold morphing and SBDD approach led to the discovery of the 1,4-disubstituted indazole series as a novel class of GKAs that potently activate GK in enzyme and cell assays. anti-diabetic OGTT efficacy was demonstrated with 29 in a rodent models of type 2 diabetes.
Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Drug Discovery , Enzyme Activators/pharmacology , Glucokinase/metabolism , Indazoles/pharmacology , Administration, Oral , Allosteric Regulation/drug effects , Animals , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/metabolism , Dose-Response Relationship, Drug , Enzyme Activators/administration & dosage , Enzyme Activators/chemistry , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Ether-A-Go-Go Potassium Channels/metabolism , Glucose Tolerance Test , Humans , Indazoles/administration & dosage , Indazoles/chemistry , Mice , Mice, Inbred C57BL , Mice, Obese , Models, Molecular , Molecular Structure , Potassium Channel Blockers/pharmacology , Structure-Activity RelationshipABSTRACT
Apoptosis signal-regulating kinase 1 (ASK1/MAP3K) is a mitogen-activated protein kinase family member shown to contribute to acute ischemia/reperfusion injury. Using structure-based drug design, deconstruction, and reoptimization of a known ASK1 inhibitor, a lead compound was identified. This compound displayed robust MAP3K pathway inhibition and reduction of infarct size in an isolated perfused heart model of cardiac injury.
ABSTRACT
Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays. Anti-diabetic OGTT efficacy was demonstrated with 54 in a mouse model of type 2 diabetes.
Subject(s)
Diabetes Mellitus, Experimental/enzymology , Drug Design , Enzyme Activators/pharmacology , Glucokinase/metabolism , Hypoglycemic Agents/pharmacology , Pyridones/pharmacology , Animals , Crystallography, X-Ray , Diabetes Mellitus, Experimental/drug therapy , Disease Models, Animal , Enzyme Activation/drug effects , Enzyme Activators/administration & dosage , Enzyme Activators/chemistry , Glucose Tolerance Test , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/chemistry , Mice , Mice, Inbred C57BL , Mice, Obese , Models, Molecular , Molecular Structure , Pyridones/administration & dosage , Pyridones/chemistry , Structure-Activity RelationshipABSTRACT
Diethyldithiodicarbonate (DDD), a cheap and easily prepared compound, is found to be a rapid and efficient sulfurizing reagent in solid phase synthesis of phosphorothioate oligodeoxyribonucleotides via the phosphoramidite approach. Product yield and quality based on IP-LC-MS compares well with high quality oligonucleotides synthesized using phenylacetyl disulfide (PADS) which is being used for manufacture of our antisense drugs.
Subject(s)
Carbonates/chemistry , Oligonucleotides/chemical synthesis , Sulfides/chemistry , Sulfur/chemistry , Thionucleotides/chemical synthesis , Indicators and Reagents , Oligonucleotides/chemistry , Thionucleotides/chemistryABSTRACT
A new reagent immobilized on solid support allowing for solid-phase synthesis of oligonucleotides with a 3'-terminal phosphorothioate monoester is described. The support is compatible with phosphoramidite chemistry for automated oligonucleotide synthesis. Final deprotection with ammonia under standard conditions leads to oligonucleotide 3'-terminal phosphorothioate.